NASDAQ$ICUI
ICU Medical Inc. · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported third quarter 2022 results with revenue of $597.9 million and adjusted diluted earnings per share of $1.75.
ICU Medical announced third quarter 2022 results with revenue of $597.9 million, GAAP gross profit of $186.4 million, and a GAAP net loss of $(13.2) million, or $(0.55) per diluted share. Adjusted diluted earnings per share was $1.75, and adjusted EBITDA was $92.6 million. The company reaffirmed its full year 2022 guidance but expects to end the fiscal year towards the lower end of the guidance range due to the impact primarily from foreign currency exchange rates.
- Third quarter revenue was $597.9 million, compared to $336.1 million in the same period last year.
- GAAP gross profit was $186.4 million, compared to $127.8 million in the same period last year.
- GAAP net loss was $(13.2) million, or $(0.55) per diluted share, compared to GAAP net income of $31.1 million, or $1.43 per diluted share, for the same period last year.
- Adjusted diluted earnings per share was $1.75, compared to $2.07 for the same period last year.
Headline financials
Revenue & EPS history
ICU Medical · Revenue · Quarterly
$598M
Revenue by segment
ICU Medical · $229M total across 2 segments · Q3 2022
- Consumables$141M-2.6%61.6%
- Infusion Systems$87.8M-3.2%38.4%
Forward guidance
The Company is reaffirming its full year 2022 guidance but due to the impact primarily from foreign currency exchange rates, expects to end the fiscal year towards the lower end of the guidance range. The Company’s full year 2022 GAAP net loss is estimated to be in the range of $(95) million to $(81) million and GAAP diluted loss per share estimated to be in the range of $(3.93) to $(3.35).The Company's previously provided adjusted EBITDA was in the range of $350 million to $370 million and adjusted diluted earnings per share was in the range of $6.20 to $6.80.
Tailwinds
- Adjusted EBITDA is expected to be in the range of $350 million to $370 million.
- Adjusted diluted earnings per share is expected to be in the range of $6.20 to $6.80.
Headwinds
- Full year 2022 GAAP net loss is estimated to be in the range of $(95) million to $(81) million.
- GAAP diluted loss per share is estimated to be in the range of $(3.93) to $(3.35).
- Expects to end the fiscal year towards the lower end of the guidance range due to the impact primarily from foreign currency exchange rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.3%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.3%
Avg return
30 days after
52%
38 / 73 earnings
Positive
+22.4%
Q2 2024
Best reaction
-33.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -0.8% | +10.7% | |
| Q4 2025 | +4.8% | +3.6% | -16.3% | |
| Q3 2025 | +8.2% | +7.3% | +9.9% | |
| Q1 2025 | -3.3% | -4.9% | -6.9% | |
| Q4 2024 | -2.3% | -4.1% | -6.4% | |
| Q3 2024 | -1.9% | -5.8% | -7.1% | |
| Q2 2024 | +22.4% | +19.7% | +31.2% | |
| Q1 2024 | -0.1% | +6.3% | +7.6% | |
| Q4 2023 | +6.5% | -0.2% | +1.6% | |
| Q3 2023 | -17.8% | -20.2% | -15.9% | |
| Q2 2023 | -15.2% | -15.6% | -16.8% | |
| Q1 2023 | +13.3% | +8.7% | +3.9% | |
| Q4 2022 | -3.6% | -4.2% | -7.3% | |
| Q3 2022 | +6.7% | +21.4% | +11.8% | |
| Q2 2022 | -7.4% | -4.7% | -8.0% | |
| Q1 2022 | -10.4% | -15.0% | -14.9% | |
| Q4 2021 | +5.8% | +9.0% | +4.3% | |
| Q3 2021 | +2.1% | +2.7% | -6.4% | |
| Q2 2021 | +0.7% | +1.2% | +6.1% | |
| Q1 2021 | -5.0% | -6.5% | -2.1% | |
| Q4 2020 | -5.5% | -6.8% | -4.4% | |
| Q3 2020 | +0.6% | +4.8% | +5.6% | |
| Q2 2020 | +8.8% | +5.0% | +9.8% | |
| Q1 2020 | -8.8% | -13.7% | -8.0% | |
| Q4 2019 | -4.2% | -4.8% | -8.2% | |
| Q3 2019 | +6.9% | +4.3% | +6.8% | |
| Q2 2019 | -33.3% | -31.2% | -36.6% | |
| Q1 2019 | -2.7% | -3.3% | -2.2% | |
| Q4 2018 | +2.5% | -4.9% | -2.8% | |
| Q3 2018 | -10.6% | -14.8% | -10.6% | |
| Q2 2018 | +2.2% | +2.4% | +3.7% | |
| Q1 2018 | +1.4% | +4.3% | +12.4% | |
| Q4 2017 | +4.6% | +7.5% | +9.1% | |
| Q3 2017 | +8.6% | +10.1% | +11.7% | |
| Q2 2017 | -2.9% | -2.4% | +3.4% | |
| Q1 2017 | -0.2% | -0.1% | +6.2% | |
| Q4 2016 | +0.7% | -1.0% | +1.5% | |
| Q3 2016 | -0.4% | -0.9% | +2.5% | |
| Q2 2016 | +7.5% | +6.1% | +8.6% | |
| Q1 2016 | -1.0% | — | — | |
| Q4 2015 | -8.7% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | +19.9% | — | — | |
| Q1 2015 | +7.3% | — | — | |
| Q4 2014 | +2.2% | — | — | |
| Q3 2014 | +13.6% | — | — | |
| Q2 2014 | +10.5% | — | — | |
| Q1 2014 | +3.3% | — | — | |
| Q4 2013 | +0.1% | — | — | |
| Q3 2013 | +3.0% | — | — | |
| Q2 2013 | -6.7% | — | — | |
| Q1 2013 | +1.3% | — | — | |
| Q4 2012 | +1.1% | — | — | |
| Q3 2012 | +3.7% | — | — | |
| Q2 2012 | -0.2% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q4 2011 | +1.9% | — | — | |
| Q3 2011 | +0.2% | — | — | |
| Q2 2011 | -3.9% | — | — | |
| Q1 2011 | +2.2% | — | — | |
| Q4 2010 | +0.1% | — | — | |
| Q3 2010 | -0.9% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q1 2010 | -1.0% | — | — | |
| Q4 2007 | -1.0% | — | — | |
| Q4 2009 | -1.0% | — | — | |
| Q3 2009 | -0.8% | — | — | |
| Q3 2008 | -0.8% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q2 2008 | -3.9% | — | — | |
| Q1 2009 | -3.9% | — | — | |
| Q4 2008 | -3.9% | — | — | |
| Q1 2008 | -3.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro